IBB-0979

N/A

Report date: 2026/04/08 15:42:24

Base Information

Drug NameIBB-0979
Drug Alias NameIBB0979IBB-0979
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCD276 antigen inhibitorsInterleukin 10 receptor agonists
TargetsCD276 antigenInterleukin 10 receptor
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSunHo (China) BioPharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunHo (China) BioPharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A